Clinical Updates From San Antonio – CDK 4/6 Inhibitors in HR+/HER2- Breast Cancer (Segment 1 Question)
Time limit: 0
Quiz Summary
0 of 1 Questions completed
Questions:
Information
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
Quiz complete. Results are being recorded.
Which adjuvant therapy regimen would you select for a 46-year-old postmenopausal female patient with HR+, HER2-, T3N1 early breast cancer and Ki-67 of 37%?
A. Abemaciclib + endocrine therapy 57.14%
B. Chemotherapy followed by endocrine therapy 42.86%
Which adjuvant therapy regimen would you select for a 46-year-old postmenopausal female patient with HR+, HER2-, T3N1 early breast cancer and Ki-67 of 37%?
